Search

Displaying results 4741 - 4750 of 10000 in total
  1. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. … In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol.

  2. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    [A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor.

  3. Drug

    Verubecestat

    go.drugbank.com/drugs/DB12285
    Investigational

    In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of … In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat.

  4. Drug

    Uracil mustard

    go.drugbank.com/drugs/DB00791
    Approved

    Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.

  5. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma. … Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP.

  6. Drug

    Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15683
    ApprovedInvestigational

  7. Drug

    Fenobam

    go.drugbank.com/drugs/DB12931
    Investigational

    Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance

  8. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD). … RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801.

  9. Drug

    IMCY-0141

    go.drugbank.com/drugs/DB17019
    Investigational

    IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin

  10. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

    Products: Xivubel 120 mg/ml Enjeksiyonluk Çözelti, 1 adet